Anti-Met (c-Met) (phospho Y1349) antibody [EP2367Y] (ab68141)


  • Product nameAnti-Met (c-Met) (phospho Y1349) antibody [EP2367Y]
    See all Met (c-Met) primary antibodies
  • Description
    Rabbit monoclonal [EP2367Y] to Met (c-Met) (phospho Y1349)
  • SpecificityThis antibody detects Met (c-Met) phosphorylated at tyrosine 1349.
  • Tested applicationsSuitable for: WB, IP, IHC-Pmore details
    Unsuitable for: Flow Cyt
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) corresponding to Human Met (c-Met).
    (Peptide available as ab175821)

  • Positive control
    • WB: HeLa and A431 cell lysate IHC: Human breast carcinoma tissue IP: HeLa cells
  • General notes

    This product is a recombinant rabbit monoclonal antibody.


    Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

    A trial size is available to purchase for this antibody.



Our Abpromise guarantee covers the use of ab68141 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/10000. Predicted molecular weight: 156 kDa.
IP 1/20 - 1/150.
IHC-P 1/50 - 1/100.
  • Application notesIs unsuitable for Flow Cyt.
  • Target

    • FunctionReceptor for hepatocyte growth factor and scatter factor. Has a tyrosine-protein kinase activity. Functions in cell proliferation, scattering, morphogenesis and survival.
    • Involvement in diseaseNote=Activation of MET after rearrangement with the TPR gene produces an oncogenic protein.
      Note=Defects in MET may be associated with gastric cancer.
      Defects in MET are a cause of hepatocellular carcinoma (HCC) [MIM:114550].
      Defects in MET are a cause of renal cell carcinoma papillary (RCCP) [MIM:605074]. It is a subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into common renal cell carcinoma (clear cell, non-papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma.
      Note=A common allele in the promoter region of the MET shows genetic association with susceptibility to autism in some families. Functional assays indicate a decrease in MET promoter activity and altered binding of specific transcription factor complexes.
      Note=MET activating mutations may be involved in the development of a highly malignant, metastatic syndrome known as cancer of unknown primary origin (CUP) or primary occult malignancy. Systemic neoplastic spread is generally a late event in cancer progression. However, in some instances, distant dissemination arises at a very early stage, so that metastases reach clinical relevance before primary lesions. Sometimes, the primary lesions cannot be identified in spite of the progresses in the diagnosis of malignancies.
    • Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family.
      Contains 3 IPT/TIG domains.
      Contains 1 protein kinase domain.
      Contains 1 Sema domain.
    • DomainThe kinase domain is involved in SPSB1 binding.
    • Post-translational
      Dephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365.
    • Cellular localizationMembrane.
    • Information by UniProt
    • Database links
    • Alternative names
      • AUTS9 antibody
      • c met antibody
      • D249 antibody
      • Hepatocyte growth factor receptor antibody
      • HGF antibody
      • HGF receptor antibody
      • HGF/SF receptor antibody
      • HGFR antibody
      • MET antibody
      • Met proto oncogene tyrosine kinase antibody
      • MET proto oncogene, receptor tyrosine kinase antibody
      • Met proto-oncogene (hepatocyte growth factor receptor) antibody
      • Met proto-oncogene antibody
      • Met protooncogene antibody
      • MET_HUMAN antibody
      • Oncogene MET antibody
      • Par4 antibody
      • Proto-oncogene c-Met antibody
      • RCCP2 antibody
      • Scatter factor receptor antibody
      • SF receptor antibody
      • Tyrosine-protein kinase Met antibody
      see all

    Anti-Met (c-Met) (phospho Y1349) antibody [EP2367Y] images

    • All lanes : Anti-Met (c-Met) (phospho Y1349) antibody [EP2367Y] (ab68141) at 1/5000 dilution

      Lane 1 : HeLa (Human cervix adenocarcinoma epithelial cell) serum starved for 24 h. Whole cell lysates
      Lane 2 : HeLa (Human cervix adenocarcinoma epithelial cell) serum starved for 24 h and then treated with hepatocyte growth factor at 40ng/ml for 5 min. Whole cell lysates
      Lane 3 : HeLa (Human cervix adenocarcinoma epithelial cell) serum starved for 24 h and then treated with hepatocyte growth factor at 40ng/ml for 5 min. Whole cell lysates. Then the membrane was incubated with phosphatase.

      Lysates/proteins at 15 µg per lane.

      Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution

      Predicted band size : 156 kDa
      Observed band size : 150 kDa (why is the actual band size different from the predicted?)

      Exposure time : 30 seconds

      Blocking and diluting buffer and concentration: 5% NFDM/TBST.

      The molecular weight of Met (c-Met) (phospho Y1349) and Met (c-Met) is different. Ab51067 could only recognize the pro-Met which is 190kDa, but ab68141 recognizes theβ-subunits which is 145kDa.

    • Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using ab68141 at a dilution of 1/50.
    • ab68141 at 1/150 dilution immunoprecipitating Met (c-Met) (phospho Y1349) in HeLa (human cervix adenocarcinoma) whole cell lysate observed at 150 kDa (lanes 1 and 2).

      Lane 1 (input): HeLa cells starved for 24 hours, then treated with 40 ng/mL HGF for 5 minutes whole cell lysate, 10μg
      Lane 2 (+): ab68141 + HeLa cells starved for 24 hours, then treated with 40 ng/mL HGF for 5 minutes whole cell lysate
      Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab68141 in HeLa cells starved for 24 hours, then treated with 40 ng/mL HGF for 5 minutes whole cell lysate

      For western blotting, ab68141 at 1/200 dilution was used followed by ab131366 VeriBlot for IP (HRP) at 1/1000 as the secondary antibody.

      Blocking and Diluting buffer and concentration: 5% NFDM/TBST.

    • All lanes : Anti-Met (c-Met) (phospho Y1349) antibody [EP2367Y] (ab68141) at 1/10000 dilution

      Lane 1 : A431 cell lysate, untreated
      Lane 2 : A431 cell lysate, treated with AP

      Lysates/proteins at 10 µg per lane.

      HRP-labeled goat anti-rabbit at 1/2000 dilution

      Predicted band size : 156 kDa
      Observed band size : ~150 kDa (why is the actual band size different from the predicted?)
    • Dot blot analysis of Met (c-Met) (phospho Y1349) phospho peptide (Lane 1), Met (c-Met) Non-phospho peptide (Lane 2), labelling Met (c-Met) (phospho Y1349) with ab68141 at a dilution of 1/1000. Peroxidase conjugated goat anti-rabbit IgG (H+L)) was used as the secondary antibody at a dilution of 1/2500.

      Blocking and diluting buffer: 5% NFDM/TBST.

      Exposure time: 3 minutes.

    References for Anti-Met (c-Met) (phospho Y1349) antibody [EP2367Y] (ab68141)

    This product has been referenced in:
    • Majumder B  et al. Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat Commun 6:6169 (2015). IHC-P ; Human . Read more (PubMed: 25721094) »
    • Gerdes MJ  et al. Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue. Proc Natl Acad Sci U S A 110:11982-7 (2013). ICC/IF ; Human . Read more (PubMed: 23818604) »

    See all 3 Publications for this product

    Product Wall

    Abcam guarantees this product to work in the species/application used in this Abreview.
    Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
    Sample Human Tissue sections (tumor tissue pancreas 5(orthotopic xenograft))
    Antigen retrieval step Heat mediated - Buffer/Enzyme Used: edta 1mM pH8
    Permeabilization No
    Specification tumor tissue pancreas 5(orthotopic xenograft)
    Blocking step Power block from DCS diagnosctics refHK085-5KE 10x solution, dilution in water as blocking agent for 10 minute(s) · Concentration: 10% · Temperature: RT°C
    Fixative Formaldehyde

    Abcam user community

    Verified customer

    Submitted Mar 02 2017

    Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
    Antigen retrieval step Heat mediated - Buffer/Enzyme Used: TRIS EDTA Buffer pH 9,0
    Sample Human Tissue sections (Breast Cancer)
    Specification Breast Cancer
    Permeabilization Yes - Wash Buffer from Dako with Tween
    Fixative Paraformaldehyde

    Mr. Rudolf Jung

    Verified customer

    Submitted Dec 04 2014